US Stock Market Move | The Federal Reserve plans to amend the capital reform proposal, causing bank stocks to collectively decline. JPMorgan Chase (JPM.US) fell more than 6%.
US bank stocks fall, as of the time of writing, JPMorgan Chase is down more than 6%
On Tuesday, US bank stocks fell. As of the time of writing, JPMorgan Chase (JPM.US) fell over 6%, Citigroup (C.US) fell over 3%, Barclays (BCS.US) fell over 2.7%, New York TrustCo Bank Corp NY (BK.US) fell 1.8%, HSBC (HSBC.US) fell over 2%, UBS Group AG (UBS.US) fell nearly 2%, and Bank of America Corp (BAC.US) fell over 1.7%. In terms of news, Fed Vice Chairman Barr stated that US regulatory agencies will make extensive revisions to their bank capital rules proposal, cutting the expected impact on the largest banks in half and exempting most measures for smaller banks. The regulatory agencies originally planned to increase the capital of the eight largest US banks by 19%, but the revision will reduce this amount by about half. Lending institutions including Citigroup, Bank of America Corp, and JPMorgan Chase will now face a requirement to increase their capital by 9% to cushion financial shocks.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025